HBV genotypic resistance to lamivudine in kidney recipients and hemodialyzed patients

Transplantation

Volumn 69, Issue 10, 2000, Pages 2090-2094

  Fontaine, Hélène ^a   Thiers, Valérie ^b,c   Chrétien, Yves ^b   Zylberberg, Hervé ^a   Poupon, Renée E ^b   Bréchot, Christian ^a,b   Legendre, Christophe ^a   Kreis, Henri ^d   Pol, Stanislas ^a,b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b INSERM   (France)

^c INSTITUT PASTEUR   (France)

^d SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; ARTICLE; CLINICAL ARTICLE; DNA SEQUENCE; FEMALE; FOLLOW UP; GENE AMPLIFICATION; GENE MUTATION; GENOTYPE; HEMODIALYSIS; HEPATITIS B; HUMAN; HUMAN TISSUE; KIDNEY TRANSPLANTATION; MALE; PRIORITY JOURNAL; SEROLOGY; VIRUS REPLICATION; VIRUS RESISTANCE;

EID: 0034720602     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200005270-00020     Document Type: Article

References (29)

1. Benhamou Y, Dohin E, Lunel-Fabiani F, et al. Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients. Lancet 1995; 345: 396.
2. Dienstag J, Perillo R, Schiff E, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333: 1657.
3. Lai CL, Chi-Kong C, Tung AKM, et al. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology 1997; 25: 241.
4. Hoonkoop P, Niesters HGM, De Man RAM, Osterhaus AD, Schalm SW. Lamivudine resistance in immunocompetent chronic hepatitis Br J Hepatol 1997; 26: 1393.
5. Bartholomew M, Jansen R, Jeffers L, et al. Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349: 20.
6. Allen M, Deslauriers M, Andrews W, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998; 27: 1670.
7. Lai C, Chien R, Leung N, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339: 61.
8. Fornairon S, Pol S, Legendre C, et al. The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection. Transplantation 1996; 62: 297.
9. Thervet E, Pol S, Legendre C, Gagnadoux M-F, Cavalcanti R, Kreis H. Low-dose recombinant leukocyte interferon-α treat-ment of hepatitis C viral infection in renal transplant recipients: a pilot study. Transplantation 1994; 58: 625.
10. Hiesse C, Buffet C, Neyrat N, et al. Impact of HBs antigenemia on long-term patient survival and causes of death after transplantation. Clin Transplant 1992; 46: 461.
11. Parfrey PS, Forbes RDC, Hutchinson TA, et al. The clinical and pathological course of hepatitis B liver disease in renal transplant recipients. Transplantation 1984; 37: 461.
12. Pirson Y, Alexandre GPJ, Van Ypersele de Strihou C. Long-term effect of HBs antigenemia on patient survival after renal transplantation. N Engl J Med 1977; 296: 194.
13. Pol S, Debure A, Degott C, et al. Chronic hepatitis in kidney allograft recipients. Lancet 1990; 335: 878.
14. Rostaing L, Henry S, Cisterne J, Duffaut M, Icart J, Durand D. Efficacy and safety of lamivudine on replication of recurrent hepatitis B after cadaveric renal transplantation. Transplantation 1997; 64: 11:1624.
15. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431.
16. Ling R, Mutiner D, Ahmed M, et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 24: 711.
17. Grellier L, Mutimer D, Ahmed M, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996; 348: 1212.
18. Perillo R, Rakela J, Martin P, et al. Lamivudine for suppression and/or prevention of hepatitis B when given pre/post liver transplantation (OLT). Hepatology 1997; 26: 4:260A (abstract).
19. Dienstag JL, Schiff ER, Mitchell M, et al. Extended lamivudine retreatment for chronic hepatitis B. Hepatology 1996; 188A (abstract).
20. Summers J, Mason WS. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 1982; 29: 403.
21. Seeger C, Ganem D, Varmus HE. Biochemical and genetic evidence for the hepatitis B virus replication strategy. Science 1986; 232: 477.
22. Hirsch RC, Lavine JE, Chang LJ, Varmus HE, Ganem D. Polymerase gene products of hepatitis B viruses are required for genomic RNA packaging as well for reverse transcription. Nature 1990; 344: 552.
23. Bartholomeusz A, Locarnini S. Mutations in the hepatitis B virus polymerase gene that are associated with resistance to famciclovir and lamivudine. Int Antiviral News 1997; 5: 123.
24. Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998; 27: 628.
25. De Man RA, Bartholomeusz AI, Niesters HGM, Zonderan PE, Locarnini SA. The sequential occurrence of viral mutations in a liver transplant recipient reinfected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss. J Hepatol 1998; 29: 669.
26. Nevens F, Main J, Honkoop P, et al. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology 1997; 113: 1258.
27. Mason W. The problem of antiviral therapy for chronic hepadnavirus infection. J Hepatol 1993; 17(suppl 3): 137.
28. Mutimer D, Naoumov N, Hoonkoop P. Combination of [alpha[-interferon and lamivudine therapy for α-interferon resistant chronic hepatitis B infection: results of a pilot study. J Hepatol 1998; 28: 923.
29. Xiong X, Flores C, Yang H, Toole JJ, Gibbs CS. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998; 28: 1669.